Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis - Report - MDSpire
Advertisement
Immunogenicity, Safety, and Persistence Induced by Triple- and Standard-Strength 4-Dose Hepatitis B Vaccination Regimens in Patients Receiving Hemodialysis
Immunogenicity and Safety of Triple-Strength vs Standard Hepatitis B Vaccine in Hemodialysis
Overview
This randomized controlled trial evaluated the immunogenic response, safety, and antibody persistence of triple-strength 4-dose hepatitis B vaccination compared to standard regimens in 504 hemodialysis patients. The triple-strength 4-dose regimen demonstrated superior peak antibody response rates and longer duration of protective antibodies with mild adverse reactions.
Background
Patients receiving hemodialysis are at increased risk for hepatitis B virus (HBV) infection due to exposure to blood products and compromised immunity. Standard hepatitis B vaccination regimens often yield suboptimal immune responses and rapid antibody decline in this population. Current guidelines recommend higher vaccine doses or prolonged schedules to enhance immunogenicity. However, evidence comparing triple-strength 4-dose regimens to standard dosing in hemodialysis patients remains limited, particularly in China where the HBV burden is high.
Data Highlights
Group
Vaccine Dose & Schedule
Peak Response Rate at Month 7 (%)
Response Rate at Month 30 (%)
Duration with ≥75% Protective Antibodies (months)
IM20 × 3
20 µg at 0,1,6 months (3 doses)
85.9 (134/156)
33.0 (33/100)
21.0
IM20 × 4
20 µg at 0,1,2,6 months (4 doses)
92.5 (135/146)
53.9 (56/104)
25.7 (P = .056 vs IM20 × 3)
IM60 × 4
60 µg at 0,1,2,6 months (4 doses)
95.4 (145/152)
57.3 (55/96)
29.2 (P = .034 vs IM20 × 3)
Key Findings
The triple-strength 4-dose regimen (60 µg at 0,1,2,6 months) achieved the highest peak seroconversion rate of 95.4% at month 7.
At 30 months, the triple-strength group maintained a significantly higher antibody positivity rate (57.3%) compared to the standard 3-dose group (33.0%).
The duration of protective antibody levels (≥75% of patients) was longest in the triple-strength group at 29.2 months.
Increasing the number of doses from 3 to 4 standard doses improved immunogenicity and antibody persistence, though not statistically significant compared to 3-dose regimen.
All vaccination regimens were well tolerated with only mild adverse reactions reported.
Clinical Implications
For patients receiving hemodialysis, a triple-strength 4-dose hepatitis B vaccination schedule can significantly enhance both the magnitude and durability of protective antibody responses. This regimen may provide improved long-term protection against HBV infection in this high-risk population with minimal safety concerns. Clinicians should consider adopting higher dose and prolonged schedules to optimize hepatitis B immunization efficacy in hemodialysis patients.
Conclusion
The triple-strength 4-dose hepatitis B vaccine regimen offers superior immunogenicity and longer-lasting antibody protection compared to standard dosing in hemodialysis patients, supporting its use to better prevent HBV infection in this vulnerable group.
References
Wang et al. 2023 -- Evaluation of Immunogenic Response, Safety, and Longevity of Triple-Strength Versus Standard 4-Dose Hepatitis B Vaccination in Hemodialysis Patients
